Suppr超能文献

IGF1R和INSR基因敲低在体外和体内前列腺癌中均发挥抗肿瘤作用。

Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.

作者信息

Ofer Philipp, Heidegger Isabel, Eder Iris E, Schöpf Bernd, Neuwirt Hannes, Geley Stephan, Klocker Helmut, Massoner Petra

机构信息

Division of Experimental Urology (P.O., I.H., I.E.E., H.K., P.M.), Department of Urology, Medical University, 6020 Innsbruck, Austria; Division of Genetic Epidemiology (B.S.), Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University, 6020 Innsbruck, Austria; Department of Internal Medicine IV (N.H.), Medical University, 6020 Innsbruck, Austria; and Division of Molecular Pathophysiology (S.G.), Biocenter, Medical University, 6020 Innsbruck, Austria.

出版信息

Mol Endocrinol. 2015 Dec;29(12):1694-707. doi: 10.1210/me.2015-1073. Epub 2015 Oct 9.

Abstract

The IGF network with its main receptors IGF receptor 1 (IGF1R) and insulin receptor (INSR) is of major importance for cancer initiation and progression. To date, clinical studies targeting this network were disappointing and call for thorough analysis of the IGF network in cancer models. We highlight the oncogenic effects controlled by IGF1R and INSR in prostate cancer cells and show similarities as well as differences after receptor knockdown (KD). In PC3 prostate cancer cells stably transduced with inducible short hairpin RNAs, targeting IGF1R or INSR attenuated cell growth and proliferation ultimately driving cells into apoptosis. IGF1R KD triggered rapid and strong antiproliferative and proapoptotic responses, whereas these effects were less pronounced and delayed after INSR KD. Down-regulation of the antiapoptotic proteins myeloid cell leukemia-1 and survivin was observed in both KDs, whereas IGF1R KD also attenuated expression of prosurvival proteins B cell lymphoma-2 and B cell lymphoma-xL. Receptor KD induced cell death involved autophagy in particular upon IGF1R KD; however, no difference in mitochondrial energy metabolism was observed. In a mouse xenograft model, induction of IGF1R or INSR KD after tumor establishment eradicated most of the tumors. After 20 days of receptor KD, tumor cells were found only in 1/14 IGF1R and 3/14 INSR KD tumor remnants. Collectively, our data underline the oncogenic functions of IGF1R and INSR in prostate cancer namely growth, proliferation, and survival in vitro as well as in vivo and identify myeloid cell leukemia-1 and survivin as important mediators of inhibitory and apoptotic effects.

摘要

以其主要受体胰岛素样生长因子受体1(IGF1R)和胰岛素受体(INSR)为核心的IGF网络,在癌症的发生和发展过程中起着至关重要的作用。迄今为止,针对该网络的临床研究结果令人失望,这就需要在癌症模型中对IGF网络进行深入分析。我们着重阐述了IGF1R和INSR在前列腺癌细胞中所控制的致癌作用,并展示了受体敲低(KD)后两者的异同。在稳定转导了可诱导短发夹RNA的PC3前列腺癌细胞中,靶向IGF1R或INSR可减弱细胞生长和增殖,最终促使细胞凋亡。IGF1R敲低引发了快速且强烈的抗增殖和促凋亡反应,而INSR敲低后的这些效应则不那么明显且出现延迟。在两种敲低情况下均观察到抗凋亡蛋白髓系细胞白血病-1和存活素的下调,而IGF1R敲低还减弱了促生存蛋白B细胞淋巴瘤-2和B细胞淋巴瘤-xL的表达。受体敲低诱导的细胞死亡尤其在IGF1R敲低时涉及自噬;然而,未观察到线粒体能量代谢的差异。在小鼠异种移植模型中,肿瘤形成后诱导IGF1R或INSR敲低可根除大多数肿瘤。受体敲低20天后,仅在1/14的IGF1R敲低和3/14的INSR敲低的肿瘤残余物中发现肿瘤细胞。总体而言,我们的数据强调了IGF1R和INSR在前列腺癌中的致癌功能,即在体外和体内的生长、增殖和存活,并确定髓系细胞白血病-1和存活素是抑制和凋亡效应的重要介质。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/2545/4669362/fbfa0097aa51/zmg9991556150001.jpg

相似文献

1
Both IGF1R and INSR Knockdown Exert Antitumorigenic Effects in Prostate Cancer In Vitro and In Vivo.
Mol Endocrinol. 2015 Dec;29(12):1694-707. doi: 10.1210/me.2015-1073. Epub 2015 Oct 9.
3
Systems Analysis of Insulin and IGF1 Receptors Networks in Breast Cancer Cells Identifies Commonalities and Divergences in Expression Patterns.
Front Endocrinol (Lausanne). 2020 Jul 7;11:435. doi: 10.3389/fendo.2020.00435. eCollection 2020.
5
Highly specific role of the insulin receptor in breast cancer progression.
Endocr Relat Cancer. 2015 Apr;22(2):145-57. doi: 10.1530/ERC-14-0490.
6
InsR/IGF1R Pathway Mediates Resistance to EGFR Inhibitors in Glioblastoma.
Clin Cancer Res. 2016 Apr 1;22(7):1767-76. doi: 10.1158/1078-0432.CCR-15-1677. Epub 2015 Nov 11.
7
Non-small cell lung cancer cell survival crucially depends on functional insulin receptors.
Endocr Relat Cancer. 2015 Aug;22(4):609-21. doi: 10.1530/ERC-14-0581. Epub 2015 Jun 25.
8
Up-regulation of INSR/IGF1R by C-myc promotes TSCC tumorigenesis and metastasis through the NF-κB pathway.
Biochim Biophys Acta Mol Basis Dis. 2018 May;1864(5 Pt A):1873-1882. doi: 10.1016/j.bbadis.2018.03.004. Epub 2018 Mar 5.
9
Minireview: nuclear insulin and insulin-like growth factor-1 receptors: a novel paradigm in signal transduction.
Endocrinology. 2013 May;154(5):1672-9. doi: 10.1210/en.2012-2165. Epub 2013 Mar 18.
10
Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma models.
J Pharmacol Exp Ther. 2011 Jun;337(3):644-54. doi: 10.1124/jpet.110.178400. Epub 2011 Mar 8.

引用本文的文献

2
Nanomedicine Approaches for Autophagy Modulation in Cancer Therapy.
Small Sci. 2025 Apr 11;5(6):2400607. doi: 10.1002/smsc.202400607. eCollection 2025 Jun.
3
The signaling landscape of insulin-like growth factor 1.
J Biol Chem. 2025 Jan;301(1):108047. doi: 10.1016/j.jbc.2024.108047. Epub 2024 Dec 3.
4
Therapeutic targets of formononetin for treating prostate cancer at the single-cell level.
Aging (Albany NY). 2024 Jun 13;16(12):10380-10401. doi: 10.18632/aging.205935.
5
Structural Models for a Series of Allosteric Inhibitors of IGF1R Kinase.
Int J Mol Sci. 2024 May 14;25(10):5368. doi: 10.3390/ijms25105368.
6
Structural Models for a Series of Allosteric Inhibitors of IGF1R Kinase.
bioRxiv. 2024 May 9:2024.04.04.588115. doi: 10.1101/2024.04.04.588115.
7
Targeting autophagy in prostate cancer: preclinical and clinical evidence for therapeutic response.
J Exp Clin Cancer Res. 2022 Mar 22;41(1):105. doi: 10.1186/s13046-022-02293-6.
8
Diagnostic and therapeutic biomarkers in colorectal cancer: a review.
Am J Cancer Res. 2022 Feb 15;12(2):661-680. eCollection 2022.
9
Inhibition of Janus Kinase 1 synergizes docetaxel sensitivity in prostate cancer cells.
J Cell Mol Med. 2021 Sep;25(17):8187-8200. doi: 10.1111/jcmm.16684. Epub 2021 Jul 28.

本文引用的文献

1
The insulin-like growth factor (IGF) axis as an anticancer target in prostate cancer.
Cancer Lett. 2015 Oct 28;367(2):113-21. doi: 10.1016/j.canlet.2015.07.026. Epub 2015 Jul 29.
2
Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy.
Oncotarget. 2015 Mar 20;6(8):6105-22. doi: 10.18632/oncotarget.3368.
5
Phase II randomized study of figitumumab plus docetaxel and docetaxel alone with crossover for metastatic castration-resistant prostate cancer.
Clin Cancer Res. 2014 Apr 1;20(7):1925-34. doi: 10.1158/1078-0432.CCR-13-1869. Epub 2014 Feb 17.
6
Self-consumption: the interplay of autophagy and apoptosis.
Nat Rev Mol Cell Biol. 2014 Feb;15(2):81-94. doi: 10.1038/nrm3735. Epub 2014 Jan 8.
7
Cancer statistics, 2014.
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29. doi: 10.3322/caac.21208. Epub 2014 Jan 7.
8
The rheostat in the membrane: BCL-2 family proteins and apoptosis.
Cell Death Differ. 2014 Feb;21(2):206-15. doi: 10.1038/cdd.2013.153. Epub 2013 Oct 25.
9
BAD dephosphorylation and decreased expression of MCL-1 induce rapid apoptosis in prostate cancer cells.
PLoS One. 2013 Sep 5;8(9):e74561. doi: 10.1371/journal.pone.0074561. eCollection 2013.
10
A novel small-molecule inhibitor of mcl-1 blocks pancreatic cancer growth in vitro and in vivo.
Mol Cancer Ther. 2014 Mar;13(3):565-75. doi: 10.1158/1535-7163.MCT-12-0767. Epub 2013 Sep 9.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验